Group 1 - The core viewpoint of the news is that Hansoh Pharmaceutical (03692) is experiencing a significant drop in stock price due to a planned share placement at a discount, which aims to raise funds for various R&D initiatives [1][2] Group 2 - Hansoh Pharmaceutical's stock fell over 7% in early trading, currently down 6.03% at HKD 36.48, with a trading volume of HKD 270 million [1] - The company plans to place 108 million shares at HKD 36.3 each, representing a discount of approximately 6.49% from the previous closing price of HKD 38.82 [1] - The net proceeds from the placement are expected to be around HKD 38.97 billion, with approximately 65% allocated for R&D of new innovative drugs in oncology, autoimmune, central nervous system, and metabolic diseases [1] - About 25% of the funds will be used to build new innovative drug production facilities and R&D laboratories, as well as upgrade existing facilities [1] - The remaining 10% will be allocated for working capital and other general corporate purposes [1] Group 3 - The company reported a mid-year revenue of HKD 74.34 billion, a year-on-year increase of 14.3%, and a net profit attributable to shareholders of HKD 31.35 billion, up 15.0% year-on-year [2] - The performance exceeded expectations, primarily due to milestone payments from the collaboration with GSK [2] - Revenue from innovative drugs and collaborative products reached HKD 61.45 billion, a 22.1% increase year-on-year, accounting for 82.7% of total revenue, up 5.3 percentage points year-on-year [2] - Collaborative revenue was HKD 16.56 billion, mainly from the upfront payment for the oral GLP-1 licensed to Merck and milestone payments from GSK [2] - In June 2025, the company licensed overseas rights for the GLP-1/GIP receptor agonist HS-20094 to Regeneron, receiving an upfront payment of USD 80 million and milestone payments of USD 1.93 billion, which will enhance performance in the second half of 2025 [2]

Core Viewpoint - Hansoh Pharmaceutical (03692) is facing a decline in stock price following the announcement of a share placement and the release of its interim financial results, which showed strong revenue and profit growth. Group 1: Share Placement Announcement - Hansoh Pharmaceutical plans to place 108 million shares at a price of HKD 36.3 per share, representing a discount of approximately 6.49% compared to the previous closing price of HKD 38.82 [1] - The net proceeds from the placement are expected to be around HKD 38.97 billion, with approximately 65% allocated for the research and development of innovative drugs in oncology, autoimmune, central nervous system, and metabolic diseases [1] - About 25% of the proceeds will be used to build new innovative drug production facilities and R&D laboratories, as well as upgrade existing R&D labs and production facilities [1] - The remaining 10% will be allocated for working capital and other general corporate purposes [1] Group 2: Interim Financial Results - For the first half of the year, the company reported revenue of HKD 74.34 billion, reflecting a year-on-year growth of 14.3% [2] - The net profit attributable to shareholders was HKD 31.35 billion, marking a year-on-year increase of 15.0% [2] - The revenue from innovative drugs and collaborative products reached HKD 61.45 billion, up 22.1% year-on-year, accounting for 82.7% of total revenue, an increase of 5.3 percentage points year-on-year [2] - Collaborative revenue amounted to HKD 16.56 billion, primarily driven by upfront payments for the oral GLP-1 licensed to Merck and milestone payments from GSK [2] - In June 2025, the company licensed overseas rights for the GLP-1/GIP receptor agonist HS-20094 to Regeneron, receiving an upfront payment of USD 80 million and milestone payments totaling USD 1.93 billion, which will enhance performance in the second half of 2025 [2]

Core Viewpoint - The company has raised its profit forecasts for 2025 and 2026 by 4.8% and 3.4% respectively, due to the growth of Amgen's product and BD-related payments, leading to a target price increase of 93.1% to HKD 45.00, reflecting a significant upside potential [1] Group 1: Financial Performance - The company's 1H25 performance exceeded expectations, with revenue of CNY 74.34 billion, a year-on-year increase of 14.3%, and a net profit of CNY 31.35 billion, up 15.0% [2] - The innovative drug revenue reached CNY 61.45 billion, growing by 22.1% year-on-year, accounting for 82.7% of total revenue, an increase of 5.3 percentage points year-on-year [3] - The oncology segment generated revenue of CNY 45.3 billion, a 21.3% increase year-on-year, primarily driven by the growth of Amgen's product and milestone payments from GSK [3] Group 2: Product Pipeline and Development - The core product Amgen has received approval for four indications in China, with expectations for additional approvals in 2H25 [4] - The company has initiated several clinical trials for its innovative drugs, including HS-20093 and HS-20089, with plans for further clinical research by partners [4] - The company aims to accelerate its license-in projects and overseas authorizations for its pipeline [4]

Group 1 - The core point of the news is that Hansoh Pharmaceutical (03692) experienced a significant drop in stock price after announcing a placement of 108 million shares at a discount, with proceeds aimed at funding various R&D initiatives [1] - The company reported a revenue of 7.434 billion yuan for the first half of the year, representing a year-on-year growth of 14.3%, and a net profit attributable to shareholders of 3.135 billion yuan, up 15.0% year-on-year [2] - The revenue from innovative drugs and collaborative products reached 6.145 billion yuan, a year-on-year increase of 22.1%, accounting for 82.7% of total revenue, with collaborative income contributing 1.656 billion yuan [2] Group 2 - Approximately 65% of the net proceeds from the share placement will be allocated to the development of new innovative drugs in areas such as oncology and autoimmune diseases [1] - About 25% of the funds will be used for constructing new innovative drug production facilities and upgrading existing R&D laboratories [1] - The company has entered into a licensing agreement for the GLP-1/GIP receptor agonist HS-20094, with an upfront payment of 80 million USD and milestone payments totaling 1.93 billion USD, which is expected to enhance performance in the second half of 2025 [2]

此次配售事项预计所得款项净额约为38.97亿港元，所得款项净额的计划用途如下：约65%用于创新药 物研发及许可(涵盖抗肿瘤、自身免疫、中枢神经系统及新陈代谢疾病等领域)；约25%用于兴建新的创 新药物生产设施及研发实验室，以及升级现有设施；约10%用于营运资金及一般企业用途。 翰森制药公告，与配售代理订立配售协议。公司将以每股36.30港元的配售价，配售1.08亿股股份，占扩 大后总股本的约1.78%。此次配售价较前一交易日收盘价38.82港元/股折让约6.49%。 ...

Group 1: Hansoh Pharmaceutical (3692 HK) - The company is experiencing strong growth driven by innovative drugs and business development (BD) collaborations, with a 14% year-on-year revenue increase to 7.4 billion RMB in 1H25, including 1.7 billion RMB from collaborations [1] - Product sales, excluding collaboration income, grew by 13%, with innovative drug revenue increasing by 22% to 6.1 billion RMB, accounting for 82.7% of total revenue [1] - The company raised its full-year revenue guidance to a high double-digit percentage, maintaining sales targets for Amelot and overall innovative drugs at 6 billion and 10 billion RMB, respectively [1] Group 2: Amelot's Clinical Applications - Amelot's rapid market penetration is primarily driven by its first-line NSCLC indication, with additional approvals for adjuvant and III phase maintenance treatments in the first half of the year [2] - The sales peak forecast for Amelot has been raised to 9.7 billion RMB, with expectations of limited price reductions during the upcoming medical insurance negotiations [2] Group 3: China Biologic Products (1177 HK) - The company reported an 11% year-on-year revenue growth to 17.6 billion RMB in 1H25, driven by innovative product sales and investment income, with adjusted net profit increasing by 101% [3] - Revenue from innovative products grew by 27% to 7.8 billion RMB, contributing 44.4% to total revenue, an increase of 5.8 percentage points year-on-year [3] - The company maintains its guidance for full-year revenue to achieve double-digit growth [3] Group 4: Long-term Growth Drivers - The company is developing a comprehensive pipeline with differentiated self-research products, expecting significant BD opportunities from 2H25 to 2026, focusing on various innovative drug candidates [4][6] - The acquisition of Lixin Pharmaceutical has further expanded the company's oncology pipeline, with management projecting over 35 innovative products by 2027, contributing 60% to revenue [6] Group 5: Tongcheng Travel (780 HK) - The company’s Q2 performance met expectations, with a projected 15% year-on-year revenue growth in core OTA business for Q3, driven by a 10-15% increase in accommodation nights [7] - The full-year core OTA business is expected to grow by 16%, with operating profit margins improving by approximately 2 percentage points due to strategic shifts towards enhancing user ARPU and profitability in new business areas [7]

8月20日早间，翰森制药在港交所公告，于2025年8月20日（交易时段前），公司、整体协调人及配售代 理订立配售协议，据此，公司同意以配售价每股36.30港元配售1.08亿股股份。配售事项所得款项净额预 期约38.97亿港元，约65%将用于抗肿瘤、自身免疫、中枢神经系统及新陈代谢疾病等治疗领域的新创 新药物研发，及创新药物及创新技术平台的许可；约25%将用于兴建新的创新药物生产设施及研发实验 室，及升级集团现有的研发实验室及生产设施；约10%将用于营运资金及其他一般企业用途。 ...

翰森制药主要在中国从事药品的研发、生产及销售。所得款项中，约39.0亿港元将用于创新药物研发、 许可、设施建设及升级和一般企业用途。本次发行根据股东大会授予的一般授权实施，预计于2025年8 月27日完成。 来源：新浪港股-好仓工作室 2025年8月20日，翰森制药（股份代号：3692）公告称，通过一般授权以"配售新股份"方式融资，发行 108,000,000股（约1.1亿股），募集约39.2亿港元，扣除费用后净得约39.0亿港元。本次融资由花旗、摩 根士丹利担任配售代理。 配售新股份配售价36.30港元，较前一交易日收市价38.82港元折让约6.5%，较前五个交易日平均收市价 折让约3.9%。配售股份占现有已发行股本约1.8%，完成后占扩大股本约1.8%。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息， ...

Group 1 - The company, Hansoh Pharmaceutical (03692), has entered into a placement agreement to issue 108 million shares at a price of HKD 36.30 per share, representing approximately 1.78% of the enlarged issued share capital post-placement [1] - The placement price of HKD 36.30 is approximately 6.49% lower than the closing price of HKD 38.82 on August 19, 2025 [1] Group 2 - The net proceeds from the placement, after deducting commissions, fees, and transaction costs, are estimated to be approximately HKD 3.897 billion, with a net price per share of about HKD 36.08 [2] - The company plans to allocate approximately 65% of the net proceeds for the research and development of new innovative drugs in areas such as oncology, autoimmune diseases, central nervous system, and metabolic diseases, as well as licensing innovative drugs and technology platforms [2] - Approximately 25% of the proceeds will be used for constructing new innovative drug production facilities and R&D laboratories, and upgrading existing R&D laboratories and production facilities [2] - The remaining 10% will be allocated for working capital and other general corporate purposes [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國、或在刊發或派發本公告屬違法的任何其他司法 管轄區內刊發或派發。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本公告並不構成在美國購買或認購任何證券之要約或招攬，或構成其中部分。本公告所述證券 並未且將不會根據美國一九三三年證券法（「美國證券法」）登記，且除非根據美國證券法作出登 記或獲豁免或為毋須根據美國證券法作出登記之交易，否則不會在美國提呈發售或出售。本公 司無意根據美國證券法登記本公告內所指之任何證券，或在美國進行證券之公開發售。 Hansoh Pharmaceutical Group Company Limited 翰森製藥集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3692） 根據一般授權 按悉數包銷基準 配售新股份 配售代理 ݷ 本公司將向聯交所申請批准配售股份上市及買賣。 配售協議項下擬進行的交易須待該 ...